Human leukemic K562 cells treated with cytosine arabinoside: Enhancement of erythroid differentiation by retinoic acid and retinol

European Journal of Haematology

Volumn 61, Issue 5, 1998, Pages 295-301

  Cortesi, R ^a   Gui, V ^a   Osti, F ^a   Nastruzzi, C ^a   Gambari, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

1 d arabinofuranosylcitosine; Erythroid differentiation; Retinoic acid

Indexed keywords

AZACITIDINE; BENZIDINE; CELLULOSE ACETATE; CYTARABINE; HEMIN; HEMOGLOBIN; RETINOIC ACID; RETINOL;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN K 562; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROID CELL; HEMOGLOBIN ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 0031772019     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01091.x     Document Type: Article

References (26)

1. LOZZIO CB, LOZZIO BB. Human myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975: 45: 321-334.
2. RUTHERFORD TR, CLEGG JB, WEATHERALL DJ. K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature 1979: 280: 164-165.
3. WHEATHERALL DJ, CLEGG JB. In: WHEATHERALL DJ, CLEGG JB, eds. The thalassemia syndromes. Oxford: Blackwell Scientific Publications, 1981: 744-780.
4. GAMBARI R, DEL SENNO L, BARBIERI R, et al. Human leukemia K562 cells: induction of erythroid differentiation by 5-azacytidine. Cell Diff 1984: 14: 87-97.
5. GAMBARI R, AMELOTTI F, PIVA R. Efficient cell proliferation and predominant accumulation of ε-globin mRNA in human leukemic K562 cells which produce mostly Hb Gower 1. Experientia 1985: 41: 673-675.
6. GAMBARI R, BARBIERI R, BUZZONI D, et al. Human leukemic K562 cells: suppression of hemoglobin accumulation by a monoclonal antibody to human transferrin receptor. Biochim Biophys Acta 1986: 886: 203-213.
7. BIANCHI SCARRA' G, ROMANI M, COVIELLO DA, et al. Terminal erythroid differentiation in the K562 cell line by 1-β-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease. Cancer Res 1986: 46: 6327-6332.
8. OKABE-KADO J, HAYASHI M, HONMA Y, HOZUMI M. Enhancement by hemin of the sensitivity of K562 humn leukemic cells to 1-β-d-arabinofuranosylcytosine. Cancer Res 1986: 46: 1239-1243.
9. RODGERS GP, RACHMILEWITZ EA. Novel treatment options in the severe β-globin disorders. Br J Haematol 1995: 91: 263-268.
10. BREITMAN TR, COLLINS SJ, KEENE B. Terminal differentiation of the human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981: 57: 1000-1004.
11. AMATRUDA TT, KOEFFLER HD. Retinoids and cells of the hematopoietic system. In: SHERMAN MI, ed. Retinoids and cells differentiation. Boca Raton, FL: CRC Press Inc., 1986: 79-103.
12. LOTAN R. Retinoids in melanoma cells. In: SHERMAN MI, ed. Retinoids and cells differentiation. Boca Raton, FL: CRC Press Inc., 1986: 61-78.
13. ELIASON JF, KAUFMANN F, TANAKA T, TSAKAGUCHI T. Antiproliferative effect of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. Br J Cancer 1993: 67: 1293-1298.
14. HONG WK, LIPPMAN SM, ITRI LM, et al. Prevention of 2nd primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990: 323: 795-801.
15. WARREL RP, FRANKEL SR, MILLER WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic-acid). N Engl J Med 1991: 324: 1385-1393.
16. SHERMAN MI. How do retinoids promote differentiation? In: SHERMAN MI, ed. Retinoids and cells differentiation. Boca Raton, FL: CRC Press Inc., 1986: 161-186.
17. MAYER H, BOLLAG W, HANNI R, RUEGG R. Retinoids, a new class of compounds with prophylactic and therapeutic activities in oncology and dermatology. Experientia 1978: 34: 1105-1119.
18. ADAMS J. Structure-activity and dose-response relationship in the neural and behavioural teratogenesis of retinoids. Neurotoxicol Teratol 1993: 15: 193-202.
19. SAURAT JH. Side effects of systemic retinoids and their clinical management. J Am Chem Dermatol 1992: 27: S23-S28.
20. YOB EH, POCHI PE. Side effects and long term toxicity of synthetic retinoids. Arch Dermatol 1987: 123: 1375-1378.
21. BENITO A, SILVA M, GRILLOT D, NUNEZ G, FFRNANDEZ-LUNA JL. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by bcl-XL. Blood 1996: 87: 3837-3843.
22. LUISI DE LUCA C, MITCHELL T, SPRIGGS D, KUFE DW. Induction of terminal differentiationin human K562 erythroleukemia cells by arabinofuranosyl cytosine. J Clin Invest 1984: 64: 821-827.
23. FRAM RM, ROBICHAUD N, BISHOW SD, WILSON JM. Interactions of cis-diamminochloroplatinum (II) with 1-β-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 1987: 47: 3360-3365.
24. KUFE DW, GRIFFIN JD, SPRIGGS D. Molecular pharmacology of cytosine arabinoside. In: GALE RP, GOLDE DW, eds. Leukemia: recent advances on biology and treatment. New York: AR Liss, 1985: 547-561.
25. CIOE' L, MCNAB A, HUBBELL HR, MEO P, CURTIS P, ROVERA G. Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butiric acid. Cancer Res 1981: 41: 237-243.
26. GAMBARI R, BARBIERI R, BUZZONI D, et al. Human leukemic K562 cells: suppression of hemoglobin accumulation by a monoclonal antibody to human transferrin receptor. Biochim Biophys Acta 1986: 886: 203-213.